Evidence map›Paper›PMID 27803741›Full record

ReviewTherapeutic advances in gastroenterology2016

The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care.

Marina De Rosa, Daniela Rega, Valeria Costabile, Francesca Duraturo, Antonello Niglio, Paola Izzo, Ugo Pace, Paolo Delrio

Abstract readReview
In one paragraph

Review in Therapeutic advances in gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Modulation ofPeerJ · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Expression of specific microRNAs in tissue and plasma in colorectal cancer.Journal of pathology and translational medicine · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marina De RosaDepartment of Molecular Medicine and Medical Biotechnology, University of Naples 'Federico II ', I-80131 Naples, Italy.
Daniela RegaColorectal Surgical Oncology-Abdominal Oncology Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, 'Fondazione Giovanni Pascale' IRCCS, I-80131 Naples, Italy.
Valeria CostabileDepartment of Molecular Medicine and Medical Biotechnology, University of Naples 'Federico II ', I-80131 Naples, Italy.
Francesca DuraturoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples 'Federico II ', I-80131 Naples, Italy.
Antonello NiglioColorectal Surgical Oncology-Abdominal Oncology Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, 'Fondazione Giovanni Pascale' IRCCS, I-80131 Naples, Italy.
Paola IzzoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples 'Federico II ', I-80131 Naples, Italy.
Ugo PaceColorectal Surgical Oncology-Abdominal Oncology Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, 'Fondazione Giovanni Pascale' IRCCS, I-80131 Naples, Italy.
Paolo DelrioColorectal Surgical Oncology-Abdominal Oncology Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, 'Fondazione Giovanni Pascale' IRCCS, I-80131 Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer has been ranked the third and second most prevalent of all cancers in men and women, respectively, and it represents the fourth most common cause of cancer deaths. In 2012, there were 1.4 million estimated cases of colorectal cancer worldwide, and 700,000 estimated deaths, which implies significant impact on public health, especially in economically-developed countries. In recent years, there has been an increase in the number of tumors, although this has been accompanied by decreased mortality, due to more appropriate and available information, earlier diagnosis, and improvements in treatment. Colorectal cancers are characterized by great genotypic and phenotypic heterogeneity, including tumor microenvironment and interactions between healthy and cancer cells. All of these traits confer a unique peculiarity to each tumor, which can thus be considered as an individual disease. Well conducted molecular and clinical characterization of each colorectal cancer is essential with a view to the implementation of precision oncology, and thus personalized care. This last aims at standardization of therapeutic plans chosen according to the genetic background of each specific neoplasm, to increase overall survival and reduce treatment side effects. Thus, prognostic and predictive molecular biomarkers assume a critical role in the characterization of colorectal cancer and in the determination of the most appropriate therapy.

Indexed as

colorectal cancer epidemiologycolorectal cancer molecular heterogeneitycolorectal cancer tumorigenesispredictive biomarkersprognostic biomarkers

Identifiers

PMID27803741
PMCPMC5076770

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.